Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 0.2% Higher – Still a Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price was up 0.2% during mid-day trading on Monday . The company traded as high as $0.25 and last traded at $0.24. Approximately 39,010,846 shares traded hands during trading, a decline of 68% from the average daily volume of 120,864,856 shares. The stock had previously closed at $0.24.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Friday, January 17th. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Up 1.4 %

The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The firm has a fifty day moving average of $0.26 and a 200 day moving average of $0.29.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. As a group, equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.